Epidemiology of diabetic nephropathy in Spain  by Martínez-Castelao, Alberto et al.
Kidney International, Vol. 68, Supplement 99 (2005), pp. S20–S24
Epidemiology of diabetic nephropathy in Spain
ALBERTO MARTı´NEZ-CASTELAO, FERNANDO DE ALVARO, and JOSE´ LUIS GO´RRIZ
Hospital Universitario Bellvitge, IDIBELL, Hospitalet Llobregat, Barcelona, Spain; H.U. La Paz, Madrid, Spain; and H.U. Dr
Peset, Valencia, GEENDIAB, SEN, Spain
Epidemiology of diabetic nephropathy in Spain.
Background. The incidence of diabetes mellitus (DM) has
increased persistently in recent years and is becoming an epi-
demic. Some have estimated that 4.4% of the world’s population
will be diabetic by the year 2030. The increase incidence of DM
has been accompanied by an increased incidence in diabetic
nephropathy (DN), the main cause of end-stage renal disease.
Methods and Results. In 1996, a pharmaco-economic study
estimated that 162,000 people in Spain had type 1 DM and
1,354,900 had type 2 DM. More recent studies have estimated
that 6% to 10% of the Spanish population might be diabetic.
This percentage is higher in some autonomous communities,
such as Canarias, in which 12% of the population is thought
to have DM. Based on these studies, we estimate that more
than 33,000 residents of Canarias have DN associated with type
1 DM, and more than 405,000 have DN associated with type
2 DM. The percentage of diabetic patients starting renal re-
placement therapy each year is currently around 21% in Spain
but much higher (35%) in Canarias, which equates to 78 pa-
tients per million population (pmp) per year. In Catalonia, the
number of DM patients entering renal replacement therapy has
increased from 8.6 pmp per year in 1984 to 32.4 pmp per year in
2003. We estimate that the systematic application of converting
enzyme inhibitors or angiotensin receptor blockers could save
more than €2.690 million over 15 years in Spain.
Conclusion. This epidemic could be prevented, or its impact
reduced, through multifactorial and multidisciplinary early in-
tervention, under the observance of guides, Spanish consen-
sus documents, and clinical practice recommendations, together
with an integrated educational program aimed at people with
diabetes and the improvement of the standard of medical care.
Diabetes mellitus (DM) is a growing worldwide epi-
demic. The World Health Report of 1977 projects a per-
sistent increase in the prevalence of DM for the next
20 years [1]. There are more than 140 million diabetics
worldwide, but probably only about 60 million of them
have been diagnosed with DM [2]. A study recently pub-
lished by Wild et al [3] estimates an increase in the global
prevalence of DM from 2.8% of the world’s population
in 2000 to 4.4% in 2030. That means more than 366 mil-
lion people would be affected by this systemic metabolic
illness.
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PREVALENCE OF DM IN SPAIN
In 1996, the Pharmaco-economic Study of Diabetic
Nephropathy in Spain estimated the prevalence of type
1 DM as 0.41% or 162,000 people, and 3.43% for type 2
DM or 1,354,900 people [4].
In 2000, the International Diabetes Federation esti-
mated that 1,922,000 Spanish people had DM [5], and the
International Diabetes Institute, a section of the World
Health Organization, estimated the number of Spaniards
with DM at about 1,945,000 [6].
If we take into account the World Health Organiza-
tion criteria for the diagnosis of DM (i.e., basal glucose
≥140 mg%), an estimated 7% of the Spanish population
have DM. Based on the American Diabetic Association
diagnostic criteria, the estimation increases to 9.8%.
In 1999, Castell et al [7] estimated that 10.3% of the
Catalonian people had DM. This estimation included
6.4% of the population with known DM and a further
3.9% with unknown DM. Goday estimated that, by 2002,
more than 2,000,000 people in Spain would have either
known or unknown DM [8].
DM AS THE PRIMARY CAUSE OF END-STAGE
RENAL DISEASE
In 1999, the United States Renal Data System noted
that DM had become the primary cause of end-stage re-
nal disease (ESRD) in the developed world, and caused
more ESRD than glomerulonephritis, hypertensive kid-
ney diseases, or other causes of chronic renal failure. The
estimated prevalence increased from 50 per million pop-
ulation (pmp) of patients starting renal replacement ther-
apy (RRT) in 1987 to 130 pmp in 1997 [9].
The survey of the Registry Committee of the Span-
ish Society of Nephrology (SEN) for 1998, whose data
covered 81.5% of the Spanish population, estimated that
21% of ESRD was caused by DM. At that time, 3 Spanish
autonomous communities, Asturias, Canarias, and Cat-
alonia, had above-average incidence rates of 25%, 30%,
and 25%, respectively [10] (Fig. 1).
The natural history of the evolution of diabetic
nephropathy (DN) might differ between type 1 and type
2 DM. The 5 stages of DN evolution in type 1 DM [11, 12]
S-20
Ma´rtinez-Castelao et al: Diabetic nephropathy in Spain S-21
15,0-24,9Without dat
>25,0%<10%
10,0-14,9
DN represents on average
21% of CRF patiens
starting RRT. Thre
Communities above 25%
Canarias (>30%).
Asturias & Extremadura
DIABETIC NEPHROPATHY
Committee Registry of Sociedad Española de Nefrología (1998)
Data available from 81,5% of Spanish population.
Fig. 1. Annual rate of diabetic nephropathy
for communities. Source: Spanish Society of
Nephrology Registry, 1998.
might not occur in type 2 DM [13, 14]. In type 2 DM, DM
is often discovered only after the diagnosis of proteinuria
or renal failure.
Microalbuminuria continues to be the most important
indicator of kidney dysfunction in type 1 and type 2 DM
[15] and is the first sign of incipient nephropathy. An es-
timated 20% to 40% of patients with type 2 DM go on
to develop microalbuminuria. About 23% of people with
type 1 DM develop DN, and of these, 14% develop mi-
croalbuminuria, 5% develop proteinuria, and 4% renal
failure. About 35% of patients with type 2 DM go on to
develop DN, and of these, 23% develop microalbumin-
uria, 5% proteinuria, and 7% renal failure.
The 1996 Spanish Pharmaco-economic study [4] esti-
mated that 18,147 individuals with type 1 DM and 157,212
of those with type 2 DM were affected by DN. Using the
most recent (March 2005) estimate of the total population
of Spain (43,750,000) [16], we estimate that more than
33,800 patients with type 1 DM, and 880,000 to 1,500,600
patients with type 2 DM, might be affected by DN in
Spain.
DM and DN in two Spanish communities: Canarias and
Catalonia
Canary Islands. The prevalence of DM in Canarias
has been estimated between 6% in Hierro Island [17] and
12% in the Gran Canaria Island [18]. In 2000, the Spanish
Registry of SEN noted that DM was the primary cause
of ESRD in Canarias and that 78 people pmp entered
RRT that year [19]. Estimates from Lorenzo and Martı´n-
Urcuyo were similar [20].
As part of the PAD study of the prevalence of DM and
DN in Canarias between April 2003 and August 2004,
Maceira and Lo´pez Alba [21] conducted a survey of 115
questions in 543 dialysis patients: 161 had type 1 DM and
278 had type 2 DM; 104 patients with ESRD not caused by
DM served as controls. The data showed that type 2 DM
was more prevalent than type 1 DM in Canarias, and that
DM exhibited an intense family aggregation, especially
in autochthonous people and those living in small rural
communities with low socioeconomic levels. The typical
patient with DN usually has parents or brothers with DM
or DN. A genetic study has revealed mitochondrial mu-
tations, suggesting the existence of a primigenius Canary
gene.
DM is usually diagnosed very late in this region. For
example, 40% of the patients with type 2 DM were di-
agnosed with DN when the patient entered dialysis. The
study also showed that three cardiovascular risk factors
occurred more frequently in the Canary population com-
pared with the general Spanish population cardiovascular
risk factor profile. More people in Canarias have a higher
blood total cholesterol concentration (30.4% and 8%,
respectively) and lower blood high-density lipoprotein-
cholesterol concentration (10.4% and 3%), and are more
likely to be obese (18.4% and 13.4%) than the general
Spanish population. The diet of people in Canarias also
differs from the Spanish or Mediterranean diet, and in-
cludes more dairy products, sweets, and carbohydrates,
and fewer vegetables or proteins than the general Span-
ish diet.
Catalonia. The Registry of Renal Patients in Catalo-
nia began in 1984 and registers all patients entering RRT
each year for hemodialysis, peritoneal dialysis, and renal
transplantation. The Registry of Renal Patients in Cat-
alonia shows that the number of diabetic people starting
RRT each year has increased from 8.6 pmp in 1984 to
32.4 pmp in 2003. The registry classifies patients as type
1 or type 2, but also includes DM as an accompanying
illness. If we consider only type 1 and type 2 DM, the cor-
responding rate is 21 pmp (Fig. 2). The most relevant data
show an increase in the global number of patients from
nearly 100 in 1984 to about 320 in 2003. The prevalence
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Fig. 2. The number and rates of diabetic patients starting RRT in Catalonia from 1984 to 2003. (x axis: year starting RRT). Source: Registre Malalts
Renals de Catalunya. Generalitat de Catalunya, 2004.
of patients with DM in RRT has grown from 600 or 74
pmp in 1984 to 1480 or 185 pmp at the end of 2003.
The most frequently associated comorbidities in these
patients are hypertension, peripheral vascular disease,
dyslipidemia, and cardiac disease. The 5-year survival rate
of these patients is lower in patients with DM than in
nondiabetic patients: 20% for type 1 DM versus 28% for
nondiabetic patients, and 20% for type 2 DM versus 30%
for nondiabetic patients [22].
SOCIOECONOMIC IMPLICATIONS OF RECENT
STUDIES OF DN IN SPAIN
Considering the evidence in the Lewis study [23],
the Pharmaco-economic study of 1996 [4] estimated
that systematic treatment with captopril, an angiotensin-
converting enzyme inhibitor (ACEI), of all of Spanish
people with DM could have saved more than €2.690 mil-
lion over 15 years. This estimation includes both the direct
and indirect costs of DM and its complications, including
dialysis, treatment, medication, transport, and other ex-
penses. The savings were estimated by dividing the values
for type 1 and type 2 DM, and comparing these with a
placebo group for both types of DM.
Palmer et al [25] applied the Irbesartan in Diabetic
Nephropathy Trial evidence [24] to Spanish DN patients
and estimated that early treatment with irbesartan would
save €8000 per patient over 15 to 25 years of age com-
pared with placebo-treated control patients and €13,500
compared with amlodipine-treated patients.
Another study has compared Spanish data with those
from the RENAAL study [26]. Using the estimations of
Rodrı´guez-Carmona et al [27] and after converting the
cost to the Euro currency of 2002, we have estimated the
daily cost of dialysis as €1488 per patient in the year 1996.
Considering the number of days that treatment with losar-
tan could save, we have estimated the savings as €4986
per patient over 3.5 years and €6959 over 4 years [28].
DM IN PATIENTS WITH CHRONIC KIDNEY
DISEASE STAGES 3 AND 4 NATIONAL KIDNEY
FOUNDATION/KIDNEY DISEASE OUTCOMES
QUALITY INITIATIVE IN SPAIN: THE MERENA
STUDY
In 1996, the Grupo Espan˜ol de Estudio de la Nefropatı´a
Diabe´tica began a study to compare the characteristics
and quality of life (QoL) of patients with DM starting
dialysis with nondiabetic patients in the same situation
[29]. The study showed that perceived health-related QoL
was lower in patients with DM starting RRT, and that this
poor QoL is maintained for at least 3 years [30].
However, no studies have assessed the characteristics
of patients with DM and progressive chronic kidney dis-
ease. The MERENA Study [31] included 1115 patients,
443 with DM and 672 without DM who were in stages
3 or 4 of National Kidney Foundation/Kidney Disease
Outcomes Quality Initiative. The aim of the study was to
compare the comorbid conditions present in both groups
of patients and to analyze the evolution of these comorbid
factors and mortality over a period of 3 years.
In the baseline study, patients with DM had more car-
diovascular risk factors than those without DM, were
older (P < 0.001), and had higher body mass index (P <
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0.001), worse GFR (P < 0.001), higher cholesterol (P <
0.002), triglycerides (P < 0.002), and fibrinogen (P <
0.008) concentrations, proteinuria (P < 0.001) and sys-
tolic blood pressure (P < 0.001), and pulse pressure (P <
0.001). We expect that the MERENA study will provide
interesting data on factors affecting the progression of
DN.
FACTORS AFFECTING THE PROGRESSION OF
DN: RELEVANCE OF THE
RENIN-ANGIOTENSIN SYSTEM BLOCKADE
The most important factors involved in the progres-
sion of DN are related to the degree of blood pressure
and glycemic control, dyslipidemia, cardiovascular risk
factors, and the progression of proteinuria [32–34]. Re-
cent evidence from the RENAAL study shows that the
degree of baseline proteinuria is closely related to the
evolution of DN. Patients with proteinuria ≥3 g/day reach
the primary end point faster than patients with baseline
proteinuria <3 g/day [35].
Until now, cumulative evidence has demonstrated that
renin-angiotensin system (RAS) blockade is crucial in
preventing the development and progression of DN. The
dual blockade is currently under investigation, and some
data support the value of dual blockade [36, 37]. The re-
sults of the ONTARGET study should provide more ev-
idence on this important matter. However, we believe
that RAS blockade should begin earlier than currently
used. The BENEDICT study [38] has shown that treat-
ment with trandolapril alone or in combination with a
calcium-channel blocker decreases the risk of develop-
ing microalbuminuria in normoalbuminuric patients with
type 2 DM.
The Randomized Olmesartan and Diabetes Microal-
buminuria Prevention study, currently being developed,
has the same primary end point, and includes 4400 nor-
moalbuminuric patients with type 2 DM. The study aims
to compare the efficacy of olmesartan versus placebo in
preventing microalbuminuria.
In a recent article, Hilgers and Veelken questioned
whether we should begin RAS blockade earlier, before
diabetes becomes obvious in patients at risk of develop-
ing type 2 DM [39].
HOW TO DECREASE THE INCIDENCE OF DN IN
SPAIN
In 1997, Grupo Espan˜ol de Estudio de la Nefropatı´a
Diabe´tica and SEN promoted a consensus between four
scientific societies on the detection, prevention, and treat-
ment of DN [40]. In 2002, this document was updated and
approved by seven scientific societies [41].
The application within clinical practice of these guides,
consensus documents, and clinical practice recommenda-
tions is crucial to decreasing the number of diabetic pa-
tients developing DN. We emphasize the importance of
applying these guides within the context of an integrated
educational program that addresses issues such as diet,
lifestyle changes, blood pressure control, microalbumin-
uria detection, prevention, and treatment.
The Steno 2 study has considered multifactorial in-
tervention and cardiovascular assessment in patients
with type 2 DM. Gaede et al [42] demonstrated that
intensive therapy offers additional benefits over con-
ventional therapy. Intensive treatment such as control-
ling blood pressure, glycemic control, cholesterol, and
anti-aggregation, and introducing an ACEI or an-
giotensin receptor blocker, decreases the relative risk of
developing nephropathy by 39%, retinopathy by 42%,
and autonomous neuropathy by 37%.
The last clinical recommendations of the American
Diabetic Association insist on this multifactorial inter-
vention approach to treat the diabetic patient and to op-
timize the standards of medical care. It is very important
to identify asymptomatic individuals who are likely to
have type 2 DM. [43]. Added to this integrated and multi-
disciplinary approach, we also need to prevent new-onset
DM, especially in patients being treated for hypertension.
Many studies have shown that different antihypertensive
treatments can influence the development of DM to dif-
ferent degrees. Various studies such as CAPPP, HOPE,
LIFE, INSIHT, and INVEST have reported a decrease in
the incidence of de novo DM from 34% to 14% associated
with treatment by ACEI, angiotensin receptor blocker, or
calcium-channel blockers compared with other conven-
tional therapies [44].
CONCLUSION
The incidence of DM continues to increase in Spain,
as in other Mediterranean countries and throughout the
world. The incidence differs between some autonomic
communities. This increase in DM is associated with an
increased incidence of DN and associated pathologies
causing ERSD.
The application of current standards derived from
guides, consensus documents, and clinical practice rec-
ommendations are far from optimal, and we emphasize
the importance of microalbuminuria screening.
Patients with DM need an integrated educational pro-
gram that carefully explains the disease process and
health implications. An intensive multifactorial and mul-
tidisciplinary intervention is crucial in the early stages of
DM and DN. Aggressive management of blood pressure,
glycemic control, lipids, proteinuria, and other progres-
sion factors is mandatory to decrease the incidence of
DN.
We must optimize the resources to care for patients
with DM and offer early intervention to decrease the
incidence of DM and its serious microangiopathic com-
plications, DN.
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